Press Releases

MIRA LOMA, Calif., Oct. 17, 2019 /PRNewswire/ -- Bridgecom, provider of a HIPAA-compliant, web-based patient outreach management platform, is excited to be attending the California Association of Health Plans Conference in Palm Desert, CA from October 21st – 23rd. For more tha

CARMIEL, Israel, Oct. 17, 2019 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today announced positive

HOUSTON, Oct. 17, 2019 /PRNewswire/ -- Researchers from Invitae Corporation (NYSE: NVTA), a leading medical genetics company, are presenting data showing the increasing utilit

BOSTON, Oct. 17, 2019 /PRNewswire/ -- Stealth BioTherapeutics (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of

GARDENA, Calif., Oct. 17, 2019 /PRNewswire/ -- For many, Halloween is a time of careless joy, but our dogs rarely share the same stress-free enjoyment of the holiday. But this hasn't stopped dogs owners as this year roughly 16 percent of Americans will dress their dogs up in costumes, spending over $400 million — double what was seen i

CAMBRIDGE, Mass., Oct. 17, 2019 /PRNewswire/ -- Kymera Therapeutics Inc., a biotechnology company pioneering targeted protein degradation to discover breakthrough medicines for patients, today announced the company will present preclinical data showing the discovery and characterization of novel, selective, and potent degraders of STAT3, a transcriptional regulator linke

ROCKVILLE, Md., Oct. 17, 2019 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced the presentation of two posters at the European Society of Gene & Cell Therapy (ESGCT) 27

CRANBURY, N.J., Oct. 17, 2019 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) announced that John Dodd, Ph.D., Palatin's Vice President of Pre-Clinical Development, provided a presentation on Palatin's oral colon delivery formulation, PL8177 in development for the treatment of ulcerative colitis, at the 7th CPC Sy

JERSEY CITY, N.J., Oct. 17, 2019 /PRNewswire/ -- Lawsuit Settlement News announced today that they will be expanding their focus on IVC lawsuits, effective immediately. Sources close to the litigation say that swift settlements have not been forthcoming thus far, but LSN expects to see positive developments regarding these cases by the end of 2019.IVC filters are

BRUSSELS, Oct. 17, 2019 /PRNewswire/ -- Regulated Information - Inside Information - UCB, a global biopharmaceutical company, today announced positive results from BE VIVID, the first of three Phase 3 studies evaluating the efficacy and safety of bimekizumab, an IL-17A and IL-17F inhibitor, in the treatment of adults with moderate-to-severe chronic plaque psoriasi